RYR1 and lymphedema: However, DANT has not received attention as an anti-lymphedema therapeutic, largely because the contribution of RYRs to lymph muscle contraction is regarded as minimal and the identity of the RYR subtypes (RYR1, RYR2, and RYR3) expressed by LMCs is unresolved (Atchison and Johnston, 1997; Atchison et al., 1998; Zhao and van Helden, 2003; Jo et al., 2019; Stolarz et al., 2019).